These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7050931)

  • 21. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy induced-vomiting--a practical guide for prevention and therapy].
    Jordan K; Voigt W; Schmoll HJ
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1869-72. PubMed ID: 16915549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiemetic effect of nonabine in cancer chemotherapy: a double blind study comparing nonabine and chlorpromazine.
    Archer CB; Amlot PL; Trounce JR
    Br Med J (Clin Res Ed); 1983 Jan; 286(6362):350-1. PubMed ID: 6402096
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypnosis in the prevention of chemotherapy-related nausea and vomiting in children: a prospective study.
    Jacknow DS; Tschann JM; Link MP; Boyce WT
    J Dev Behav Pediatr; 1994 Aug; 15(4):258-64. PubMed ID: 7798371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs for vomiting caused by cancer chemotherapy.
    Med Lett Drugs Ther; 1993 Dec; 35(912):124-6. PubMed ID: 8264505
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine.
    Herrstedt J
    Dan Med Bull; 1998 Sep; 45(4):412-22. PubMed ID: 9777292
    [No Abstract]   [Full Text] [Related]  

  • 31. [The magic plant as an antiemetic. Cannabinoids for treatment of nausea and vomiting].
    Kreutz S
    Pharm Unserer Zeit; 2007; 36(5):389-92. PubMed ID: 17722146
    [No Abstract]   [Full Text] [Related]  

  • 32. The difficult trials.
    Herrstedt J
    Onkologie; 2009 Feb; 32(1-2):7-8. PubMed ID: 19209012
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical trials referral resource. Cancer chemoprevention and control trials.
    Brawley OW; Cheson BD; Phillips PH
    Oncology (Williston Park); 1996 Apr; 10(4):499-500. PubMed ID: 8723279
    [No Abstract]   [Full Text] [Related]  

  • 34. Do we need new antiemetic guidelines?
    Roila F
    Support Care Cancer; 2002 Oct; 10(7):517-8. PubMed ID: 12324804
    [No Abstract]   [Full Text] [Related]  

  • 35. Antiemetic therapy.
    Gralla RJ
    Semin Oncol; 1998 Oct; 25(5):577-83. PubMed ID: 9783597
    [No Abstract]   [Full Text] [Related]  

  • 36. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.
    Holdsworth MT; Vo-Nguyen T
    Ann Pharmacother; 2005 Nov; 39(11):1903-10. PubMed ID: 16204394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiemetic guidelines: creating a more practical treatment approach.
    Koeller JM; Aapro MS; Gralla RJ; Grunberg SM; Hesketh PJ; Kris MG; Clark-Snow RA
    Support Care Cancer; 2002 Oct; 10(7):519-22. PubMed ID: 12324805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.